Abstract Background and Objectives Atrial fibrillation (AF) and the associated risk of stroke
are emerging epidemics throughout the world. Suboptimal use of oral anticoagulants for …

Objective This study incorporates the results of subgroup analyses of currently published
randomized controlled trials (RCTs) and real-world cohort studies to compare the …

Summary Background Direct oral anticoagulants (DOACs) are effective and safe alternatives
to warfarin for stroke prophylaxis for atrial fibrillation (AF). Whether this extends to patients at …

Direct oral anticoagulants (DOACs) used in nonvalvular atrial fibrillation (NVAF) are dose-
reduced in elderly and patients with impaired renal function. Only reduced dose dabigatran …

Older patients with atrial fibrillation (AF) are at higher risk of thromboembolic events and oral
anticoagulant (OAC)-related bleeding complications. This meta-analysis evaluates the …

Background: Guidelines caution against the use of non–vitamin K antagonist oral
anticoagulants in patients with extremely high (> 120 kg) or low (≤ 60 kg) body weight …

Abstract Background Direct oral anticoagulants (DOACs) are indicated for the prevention of
stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation. While no …

Background—Oral anticoagulants such as apixaban, dabigatran, and rivaroxaban are
alternatives to warfarin for preventing events in patients with atrial fibrillation. Direct …

Aim This study aimed to evaluate the label compliance of DOACs in the Chinese AF
population and explore the relationship between inappropriate DOACs dosage and clinical …

In the last 40 years, concern about the obesity epidemic has increased. Data from the
current literature highlight a strong relationship between obesity and atrial fibrillation (AF) …